Efficacy and safety of dabigatran etexilate and warfarin in ‘real world’ patients with atrial fibrillation: A prospective nationwide cohort study ONLINE FIRST

Atrial Fibrillation Wednesday, April 17th, 2013

J Am Coll Cardiology: April 1, 2013

Objective  To assess the efficacy and safety in an ‘everyday clinical practice’ population of anticoagulant-naïve patients with atrial fibrillation (AF) treated with dabigatran etexilate following its post-approval availability in Denmark, compared to warfarin.

Background  Concerns have been raised about an excess of bleeding events or myocardial infarction amongst patients treated with the new oral direct thrombin inhibitor, dabigatran etexilate.

Methods  From the Danish Registry of Medicinal Product Statistics, we identified a dabigatran-treated group and a 1:2 propensity matched warfarin-treated group of n=4978and n=8936, respectively. Comparisons on efficacy and safety outcomes were made based on Cox-proportional hazards models stratified on propensity match groups. Read more

National Minority Quality Forum Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.